A team of international researchers including those from the University of Adelaide have taken a well-known chemical reaction ...

The new findings show that ADCs, just like chemotherapy ... contributing to chemotherapy-induced peripheral neuropathy. ADCs, ...

Two decades ago, when two genetic mutations were discovered in Asia that gave scientists a better idea of how pain sensations ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, especially for MS ...

The Bcl-2 inhibitor venetoclax is highly effective and is another first- or second-line option even if this agent, like BTK inhibitors, also appears to require continuous dosing, said Stadtmauer, ...

London - Abu Dhabi – Oxford Cannabinoid Technologies (“OCT” or “the Company”) is pleased to announce the successful ...

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

NEW RESEARCH presented at EASD 2024 revealed that maternal Type 1 diabetes (T1D) provides long-term relative protection ...

THE RISING global prevalence of youth-onset Type 2 diabetes (Y-T2D) is a serious public health concern. With an aggressive ...